The Seed Investor
Early Stage Investing
Join our Newsletter  Hand-picked cannabis stocks, news & alerts straight to your inbox (100% FREE!)
  •  
  • Cannabis News
  • Marijuana Industry
  • Marijuana Investing
  • Psychedelics
  • Featured Companies
  • TSI Exclusive
  • About
    • Overview
    • Disclaimer
    • Advertise
    • Privacy Policy

Trending Now

  • MCUR’s $10 Million Financing Triples Cash Reserves, Powers Operations Strategies
  • Mind Cure Establishes Psychedelic Compound Research Program
  • Compass Pathways Files For NASDAQ Listing: Psychedelics Game-Changer
  • MindMed And Eleusis Lead The Way In Psychedelics Micro-Dosing Research
  • Why Psychedelics Micro-Dosing Applications Have The Inside Track On Commercialization
  • Cannabis Sales Soar 48% In 2019, 2020 Looking Even Stronger
Psychedelic Stocks
Exploring the companies and themes that make up this emerging and exciting new sector

Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder

2022-06-27 PSW Editor

Cybin announces receipt of its "may proceed letter" from the U.S. Food and Drug Administration (FDA) regarding its Phase 1/2a clinical trial of CYB003 for major depressive disorder (MDD).

Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights

2022-06-23 PSW Editor

Cybin Inc reports its fiscal year 2022 financial results, including progress on several pipeline initiatives, with a cash balance of CAD$53.6 million as of March 31, 2022.

Numinus Pilots Mental Health Program for Corporate Clients in Utah

2022-06-23 PSW Editor

Numinus announces a pilot program to encourage employers to offer ketamine-assisted psychotherapy to employees as a health benefit.

Cybin Acquires DMT Clinical Study from Entheon Biomedical

2022-06-07 PSW Editor

Cybin Inc announces acquiring a Phase 1 DMT study from Entheon Biomedical, at a purchase price of CAD$1 million plus additional considerations.

Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy

2022-06-02 Cybin

Cybin announces publication of EMBARK, a model of psychedelic-assisted psychotherapy that integrates leading clinical approaches to promote effective facilitation and supportive healing.

Novamind Reports Fiscal Q3 2022 Financial Results and Operating Highlights

2022-05-31 PSW Editor

Novamind Inc reports its Q3 for fiscal 2022. Quarterly revenues of CAD$3,227,352 represent a q-o-q of 32%. Novamind also expanded into the Arizona market in Q2 with its clinic operations.

Optimi Health Enters Into Psilocybin Supply Agreement With Filament Health

2022-05-31 PSW Editor

Optimi Health announces a new supply agreement with Filament Health to supply Filament with psilocybin mushrooms.

Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder

2022-05-31 PSW Editor

Cybin Inc announces the submission of an Investigational New Drug application (IND) to the FDA for a Phase 1/2a clinical trial of CYB003 for major depressive disorder (MDD).

Optimi Health Signs Psilocybin Supply Agreement With Halucenex Life Sciences Inc.

2022-05-27 PSW Editor

Optimi Health announces entering into a supply agreement with Halucenex Life Sciences Inc that "pertains to the entirety of" Optimi's recently cultivated psilocybe mushrooms.

Awakn Life Sciences Files Patent Cooperation Treaty (PCT) Application for the Treatment of Behavioral Addictions

2022-05-26 PSW Editor

Awakn Life Sciences announces filing a patent application for the treatment of behavioral addictions with ketamine-assisted psychotherapy.

Open For Business: Optimi Completes First Grow of Psilocybin Mushrooms and Introduces Head of Cultivation

2022-05-25 PSW Editor

Optimi Health announces the completion of its first crop of psilocybin mushrooms at the company's Princeton, B.C. cultivation facility.

Small Pharma Shares Business Update Ahead of Annual Financial Results

2022-05-25 PSW Editor

Small Pharma issues a corporate update, reporting R&D and IP progress, with ~CAD$40 million in cash as of February 28, 2022.

  • 1
  • 2
  • 3
  • 4
  • ...
  • 73
  • Next
Join our Newsletter
 Hand-picked cannabis stocks, news & alerts straight to your inbox (100% FREE!)

The Seed Investor Exclusive

MCUR’s $10 Million Financing Triples Cash Reserves, Powers Operations Strategies

MCUR’s $10 Million Financing Triples Cash Reserves, Powers Operations Strategies

2021-01-21
Mind Cure announces a CAD$10 million bought deal financing at a unit price of CAD$0.60. Proceeds will be directed toward product research development and related tech initiatives like its iSTRYM digital therapeutics platform.

Mind Cure Establishes Psychedelic Compound Research Program

Compass Pathways Files For NASDAQ Listing: Psychedelics Game-Changer

The Psychedelics Revolution: From ‘War on Drugs’ To Funding Psychedelic Drug Research

Eleusis Looks For Alzheimer’s Breakthrough With Micro-Dosed LSD

Psychedelic Stocks
NEWS
INDUSTRY
INVESTING
COMPANIES
EXCLUSIVE

Newsletter

Get The Seed Investor straight to your email.

Copyright © 2016-2022, The Seed Investor | About | Contact | Advertise | Privacy Policy | Disclaimer
Powered by StructureCMS
The Seed Investor